Refractory Gout and Advanced Biologics
For the small percentage of UK patients who do not respond to Allopurinol or Febuxostat (refractory gout), the market in 2026 is seeing an increase in biologic interventions.
Interleukin-1 (IL-1) Inhibitors: Medications like Canakinumab or Anakinra are increasingly used for severe flares in patients with multiple comorbidities where traditional anti-inflammatories are dangerous.
Uricosurics: Selective URAT1 inhibitors (like Dotinurad) are entering the UK market as potent alternatives for patients who are "under-excretors" of uric acid.
Hospital-Based Care: These advanced therapies are generally restricted to secondary care (Rheumatologists) due to cost and the need for specialized monitoring.
4 Views